Eli Lilly And Company

This program monitors 4000 people with schizophrenia who receive Zyprexa Relprevv, a long-acting injection. The goal is to track and reduce the risk of a rare but serious reaction called post-injection delirium/sedation syndrome (PDSS). Researchers will record how often PDSS happ…

This study tests a once-weekly injection called retatrutide to help people with obesity or overweight lose weight. About 250 participants who do not have type 2 diabetes will receive either the drug or a placebo for 65 weeks. The main goal is to see how much weight they lose and …

This phase 2 study tests whether mazdutide, a drug originally developed for diabetes, can help people with alcohol use disorder drink less. About 300 participants will receive either mazdutide or a placebo for up to 36 weeks. The study tracks drinking behaviors using a timeline f…

This phase 3 trial tests whether adding the drug abemaciclib to standard hormone therapies (anastrozole, letrozole, or fulvestrant) can help slow cancer growth in postmenopausal women with a common type of advanced breast cancer (HR+, HER2-). About 463 women participated, and the…

This study tests a once-weekly injection called retatrutide in 320 adults with type 2 diabetes and moderate to severe kidney disease who are not controlling their blood sugar well on insulin. Participants will receive either the drug or a placebo for about 14 months. The goal is …

This early-stage study tests an experimental pill called LOXO-338 in people with advanced blood cancers (like certain leukemias, lymphomas, and multiple myeloma) who have already tried standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors.…

This Phase 3 trial is testing a once-daily pill called orforglipron to see if it helps people with obesity or overweight lose weight, both in those with and without type 2 diabetes. About 1,200 participants will take either the drug or a placebo for a set period. The goal is to f…

This Phase 3 trial tests whether adding ramucirumab (a drug that blocks blood vessel growth) to the standard targeted therapy erlotinib can help people with a specific type of advanced lung cancer (EGFR-mutated NSCLC) live longer without their cancer getting worse. About 545 peop…

This phase 3 trial is testing whether retatrutide can reduce serious heart problems (like heart attacks and strokes) and slow kidney disease in 10,000 adults with a BMI of 27 or higher who already have heart or kidney disease. Participants receive either retatrutide or a placebo …

This early-phase study tests an oral drug called LY3484356 in 17 Chinese patients with advanced ER+/HER2- breast cancer. The main goals are to see how the drug moves through the body and to check its safety. Researchers will also look for signs that the drug can shrink tumors or …

This phase 3 trial is testing different ways to increase the dose of retatrutide, a weight-loss drug, in 600 people with obesity or overweight who do not have type 2 diabetes. The study lasts about 113 weeks and aims to find the safest and most effective dosing schedule for weigh…

This study tests whether baricitinib, an oral anti-inflammatory drug, is safe and effective for children aged 2 to 17 with moderate to severe atopic dermatitis (eczema). About 516 participants will receive either baricitinib or a placebo, plus standard topical steroids. The main …

This Phase 3 trial tests a daily pill called orforglipron in nearly 1,000 adults with high blood pressure and obesity or overweight. Participants take the drug or a placebo for several weeks to see if it safely lowers blood pressure and helps with weight. The study is active but …

This phase 3 trial tests a new oral hormone therapy called imlunestrant against standard hormone therapies (like tamoxifen or aromatase inhibitors) in 8,000 people with ER+/HER2- early breast cancer who have already had 2-5 years of hormone therapy and are at higher risk of recur…

This Phase 3 trial tests orforglipron, a daily tablet, against placebo for weight loss in 600 adults with obesity or overweight (without type 2 diabetes). Participants must have a BMI of 30 or higher, or 25 with related health issues like high blood pressure. The study lasts abou…

This Phase 2 trial is testing whether tirzepatide, a drug already used for diabetes and weight loss, can improve kidney health in 140 people who are overweight or obese and have chronic kidney disease (with or without type 2 diabetes). The study uses advanced MRI scans to measure…

This study tests a daily pill called selpercatinib in people with advanced solid tumors or medullary thyroid cancer that have a specific RET gene change. The goal is to see if the drug can shrink tumors and how safe it is. About 77 participants in China will take the drug, and do…

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This study tests an experimental drug called [Ac-225]-PSMA-62 in people with prostate cancer that has spread to other parts of the body. The drug delivers a small amount of radiation directly to cancer cells. The main goals are to find the safest dose and to see if it can shrink …

This Phase 3 study tests an experimental once-daily pill called orforglipron in about 487 adults who have both high blood pressure and obesity or overweight. The main goal is to see if the drug lowers blood pressure more than a placebo. Researchers will also check for changes in …

This study tests a drug called donanemab in 1500 people with early Alzheimer's disease. The goal is to see if it can slow down memory and thinking problems. Participants receive the drug or a placebo for up to 93 weeks, and researchers measure changes in their symptoms.

This study tested whether adding the drug abemaciclib to standard hormone therapy (anastrozole or letrozole) helps control advanced breast cancer in postmenopausal women. About 493 women with hormone receptor-positive, HER2-negative breast cancer that had spread or returned took …

This study tests whether baricitinib, an oral drug, is safe and effective for children aged 2 to 18 with active uveitis (eye inflammation) linked to juvenile arthritis or a related condition. Participants had not responded well to standard treatments. The main goal is to reduce e…

This early-stage study tests an experimental drug called LY3537031 in overweight, obese, and healthy volunteers. The main goal is to check safety and side effects, but researchers will also measure how much drug gets into the blood and how body weight changes. The study lasts abo…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This Phase 3 study tests an experimental drug called remternetug against a placebo in 1400 people with early Alzheimer's who are at risk for worsening memory and function. The goal is to see if the drug can delay or prevent progression. Participants may be in the study for up to …

This study tests an experimental drug called LY3541860 against a placebo in 63 adults with relapsing multiple sclerosis (MS). The goal is to see if the drug can reduce the number of new brain lesions seen on MRI scans over about 9 months. Participants receive the drug or placebo …

This early-phase trial tests the safety of combining abemaciclib with various other cancer drugs (like letrozole, tamoxifen, or trastuzumab) in 198 people with breast cancer that has spread. The goal is to find safe combinations that may help control the disease. Participants hav…

This Phase 3 study tests a weekly injection called retatrutide in about 1,946 people with severe obesity (BMI ≥35) and established heart disease. The goal is to see if it helps with weight loss and improves heart-related health measures over 113 weeks compared to a placebo. Parti…

This study tests whether the drug selpercatinib can delay the return of lung cancer in people with early-stage non-small cell lung cancer that has a specific genetic change (RET fusion). Participants have already had surgery or radiation to remove or treat their cancer. They will…

This study tests a drug called selpercatinib against standard chemotherapy for people with a certain type of advanced lung cancer (RET fusion-positive non-small cell lung cancer). The goal is to see if selpercatinib can delay cancer growth better than current treatments. About 26…

This study looks at how well and how safely the drug mirikizumab works over the long term (up to 3 years) for people with moderate to severe ulcerative colitis. About 1,058 adults who were already in earlier studies will continue treatment. The goal is to see if the drug can keep…

This study was designed to test whether volenrelaxin could help adults with chronic kidney disease by reducing protein in the urine and preserving kidney function over 24 weeks. Participants would have already been on standard blood pressure medications. However, the trial was wi…

This study tests a new weekly medicine, retatrutide, against an existing one, semaglutide, in about 1250 adults with type 2 diabetes whose blood sugar is not well controlled by metformin. The goal is to see which works better at lowering blood sugar and weight over 26 months. Par…

This study tests a new daily pill, orforglipron, to help adults with obesity or overweight who also have weight-related conditions like high blood pressure or sleep apnea lose weight. About 3,100 participants will take either the pill or a placebo for 72 weeks, with some continui…

This study tests a drug called lebrikizumab in children aged 6 months to 18 years with moderate-to-severe eczema (atopic dermatitis). The goal is to see if it improves skin condition and reduces itching compared to a placebo. About 367 participants will receive either the drug or…

This early-stage study tests an experimental pill called LOXO-260 in about 70 adults whose cancer has a specific RET gene change and has stopped responding to other targeted treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors.…

This study looks at how well and how safely the drug mirikizumab works over the long term for people with Crohn's disease. About 996 adults who were in earlier mirikizumab studies will continue treatment. The goal is to see if the drug can keep the gut healed and symptoms under c…

This study tests an oral drug called LOXO 292 in children and teens with advanced solid or brain tumors that have a specific genetic change (RET alteration). The goal is to see if the drug is safe and can shrink or control the tumors. About 36 participants will take the drug, and…

This early-phase study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct, cartilage, or brain cancers) that have specific IDH1 or IDH2 gene mutations. The main goal is to find the safest and most effective dose, while also checking for side …

This early-stage study tests an investigational drug called LY4086940 in healthy people and those with overweight, obesity, or type 2 diabetes. The main goal is to check the drug's safety and how the body processes it. About 216 participants will receive single or multiple doses …

This early-stage study tests a new drug called LY3295668 erbumine in people with neuroblastoma that has returned or not responded to standard therapy. The main goal is to check safety and find the right dose. About 71 participants will receive the drug alone or with other medicin…

This study aimed to test two drugs, bimagrumab and tirzepatide, alone or together, for helping adults with obesity or overweight and type 2 diabetes lose weight. It was planned for about 13 months but was withdrawn before enrolling any participants. The main goal was to see how m…

This study looks at how a once-weekly drug called retatrutide affects recovery from low blood sugar in people with type 2 diabetes. About 78 adults who manage their diabetes with diet, exercise, and metformin will take either the drug or a placebo for 16 weeks. Researchers will m…

This study compares the long-term effects of tirzepatide, a newer diabetes medication, with standard treatments in 780 adults who were diagnosed with type 2 diabetes within the last 4 years. Participants must be on metformin alone and have moderately high blood sugar levels. The …

This phase 3 study tested whether adding the drug abemaciclib to standard hormone therapy (fulvestrant) helps women with a common type of advanced breast cancer (HR+, HER2-) live longer without their cancer growing. About 669 women took part, receiving either the combination or f…

This study tests whether adding the drug abemaciclib to standard chemotherapy can help people with Ewing's sarcoma whose cancer has returned or not responded to treatment. About 46 children and young adults will take part. The goal is to see if the combination slows tumor growth …

This study tests a new medicine called lebrikizumab, given alone or with a steroid cream, for people with moderate-to-severe eczema (atopic dermatitis). About 300 adults will receive the drug or a placebo for up to 62 weeks. The goal is to see if it safely reduces skin redness, i…

This study tests a drug called lebrikizumab for people with moderate-to-severe hand and foot eczema. About 206 adults and teens will receive either the drug or a placebo for 16 weeks. The goal is to see if the drug clears skin lesions and reduces itching better than a placebo.

This study tests a new drug called eltrekibart in 352 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition. The goal is to find the best dose and dosing schedule to reduce abscesses and inflammation. Participants will receive either eltrekibart o…

This early-phase study tests a new drug called LY4066434 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 750 participants with pancreatic, lung, or co…

This phase 3 trial tests whether a once-daily pill called orforglipron can improve sleep apnea in 600 adults with moderate-to-severe sleep apnea who are also obese or overweight. Participants are split into two groups: those who cannot or will not use a CPAP machine, and those wh…

This study tests an experimental drug called LY3537982 in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and shrinks tumors. About 540 participants with lung, colorectal, endometrial, ovarian, pancreatic, or bile …

This early-stage study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors that have come back or spread. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The study aims to find a safe dose and see if the drug can sh…

This early-phase study tests whether combining two drugs, abemaciclib and pembrolizumab, is safe and effective for people with advanced non-small cell lung cancer or a certain type of breast cancer. About 100 participants with stage IV disease will receive the combination. The go…

This Phase 3 study tests a once-daily pill called orforglipron in 487 adults with high blood pressure who are also overweight or have obesity. The main goal is to see if it lowers blood pressure more than a placebo. Researchers will also check for weight loss and other health imp…

This study tested whether adding the drug abemaciclib to standard care helps people with stage IV lung cancer that has a KRAS mutation live longer. All 453 participants had already tried chemotherapy. Half received abemaciclib plus supportive care, the other half received erlotin…

This study tests different doses of tirzepatide in 414 adults with type 2 diabetes and obesity who are already taking metformin. The main goal is to see how much weight participants lose and how well their blood sugar is controlled over about 89 weeks. Participants are randomly a…

This study tests different dosing schedules of the drug donanemab in about 1,175 people with early symptomatic Alzheimer's disease. The goal is to find a regimen that lowers brain amyloid plaques while reducing the risk of a side effect called ARIA-E (brain swelling or small blee…

This early-phase study tests the safety of a new drug called LY3200882 in 223 adults with solid tumors. Researchers aim to find a safe dose and check if the drug can shrink tumors. The study is not yet recruiting and is actively ongoing.

This study tests a once-weekly medicine called tirzepatide in adults with type 1 diabetes who are also overweight or obese. The goal is to see if it helps control blood sugar and reduce weight safely over about 20 months. Participants continue their insulin and are randomly assig…

This study tests whether galcanezumab, a monthly injection, can prevent chronic migraines in teenagers aged 12 to 17. About 312 teens with 15 or more headache days per month will receive either the drug or a placebo for 3 months. The goal is to see if the drug safely reduces the …

This study tests whether adding a weight-loss drug (tirzepatide) to a standard psoriasis treatment (ixekizumab) helps people with moderate-to-severe plaque psoriasis who are also overweight or obese. About 250 adults will receive either ixekizumab alone or both drugs together for…

This study tests a once-weekly medicine called retatrutide in about 1000 adults with type 2 diabetes who are overweight or have obesity. The goal is to see if it helps with weight loss and, in a smaller group, improves sleep apnea. Participants receive either the drug or a placeb…

This study tests whether two drugs—bimagrumab and tirzepatide—can help adults with obesity or overweight lose weight safely. About 252 participants will receive one or both drugs or a placebo for around 70 weeks. The main goal is to see how much body weight changes from the start…

This study tests whether a new drug, retatrutide, works better than the existing drug tirzepatide for weight loss in adults with obesity. About 800 participants will receive either drug for 89 weeks, and researchers will measure changes in body weight, BMI, and other health marke…

This large Phase 3 study tests an injectable drug called lepodisiran in about 17,300 adults with high levels of lipoprotein(a), a genetic risk factor for heart disease and stroke. Participants either already have heart disease or are at high risk for a first heart event. The goal…

This study tests two drugs, LY3841136 and tirzepatide, alone or together, to help adults with obesity or overweight and type 2 diabetes lose weight. About 350 participants will take the drugs or a placebo for up to 64 weeks. The goal is to see if these treatments are safe and eff…

This study tests an investigational drug called retatrutide in 643 adults with obesity. The goal is to see if it helps maintain weight loss over about 2.5 years. Participants first take the drug for 80 weeks, then are randomly assigned to continue the drug or switch to a placebo …

This study tests whether galcanezumab, a monthly injection, can prevent migraines in children and teens aged 6 to 17 with episodic migraine. Over 500 participants received either the drug or a placebo for 3 months. The goal is to see if the drug reduces the number of migraine day…

This study tests whether adding the drug abemaciclib to standard treatment (abiraterone acetate plus prednisone) can help men with metastatic castration-resistant prostate cancer live longer without their cancer getting worse. About 393 participants will receive either the combin…

This study tests whether adding abemaciclib to fulvestrant can slow or stop the growth of a common type of advanced breast cancer (HR+, HER2-) that has worsened after initial treatment. About 368 participants will receive either the drug combo or a placebo plus fulvestrant. The g…

This study tests whether the drug ixekizumab is safe and effective for children with certain types of juvenile arthritis (enthesitis-related arthritis and juvenile psoriatic arthritis). About 101 children aged 2 to 17 years will receive either ixekizumab or the standard drug adal…

This study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. It includes 13 participants who already benefited from the drug in an earlier study and will continue treatment ever…

This study tests if tirzepatide, a once-weekly injection, can help adults with type 1 diabetes who are overweight or obese. About 905 participants will receive either tirzepatide or a placebo for up to 49 weeks. The goal is to see if the drug improves blood sugar control and help…

This early-stage study tests a new medicine, LY3849891, in people with a type of fatty liver disease (MASLD) who have a specific gene change (PNPLA3 I148M). The main goal is to check the drug's safety and how the body processes it. Researchers will also use blood tests and liver …

This study looks at the long-term safety and effectiveness of lebrikizumab for children aged 6 months to under 18 years with moderate-to-severe atopic dermatitis (eczema). About 310 participants who completed a prior study will receive lebrikizumab for up to 116 weeks. The goal i…

This study tests a once-daily pill called orforglipron against a placebo in 600 adults with obesity or overweight who also have type 2 diabetes. The goal is to see if the pill improves blood sugar levels and helps with weight loss over about 18 months. Participants must have a BM…

This study tests a drug called abemaciclib, given alone or with tamoxifen, in women with a certain type of advanced breast cancer (HR+, HER2-) that has worsened after previous treatments. The goal is to see if the combination helps keep the cancer from growing longer. About 234 w…

This study tests whether tirzepatide, a drug already used for diabetes and weight loss, can reduce the risk of serious heart problems and death in adults with obesity. Over 15,000 participants with a BMI of 27 or higher, and either existing heart disease or high risk factors, are…

This study tests whether adding the drug abemaciclib to standard chemotherapy (temozolomide) helps children and young adults with a newly diagnosed high-grade glioma live longer without the cancer growing. About 45 participants who have completed radiation therapy will receive ei…

This study tested whether adding the drug abemaciclib to standard hormone therapy helps prevent breast cancer from coming back in people with a high-risk, early-stage type called HR+/HER2-. Over 5,600 participants who had surgery for node-positive breast cancer took either the co…

This study tests whether donanemab, a monthly infusion, can delay or prevent memory and thinking problems in people who have early signs of Alzheimer's disease but no symptoms yet. About 3000 participants with a positive blood test for Alzheimer's-related proteins are being follo…

This study tests an experimental drug called LY3848575 for people with long-term nerve pain that starts in the feet and moves up the legs. About 558 participants will receive either the drug or a placebo to see if it safely reduces pain and improves daily activities. The trial la…

This study tests whether lebrikizumab can reduce itching and skin symptoms in people with moderate eczema who have a high itch burden. About 233 adults and teens will receive the drug for 24 weeks. The main goal is to see if at least 75% of skin symptoms improve or if itch scores…

This early-stage study tests a new drug called LY3549492 in 120 healthy adults who are overweight or have obesity. The main goal is to check the drug's safety and how the body processes it over about 8 weeks. Participants receive multiple doses of the drug, and researchers monito…

This study tests whether the drug mevidalen can safely improve thinking, memory, and daily function in people with mild-to-moderate Alzheimer's disease. About 300 participants will receive either mevidalen or a placebo for 26 weeks. The main goal is to see if the drug eases sympt…

This early-phase trial is testing a new drug called LY4005130 in 118 healthy volunteers to see if it is safe and how the body processes it. Participants receive either the drug or a placebo, given as an injection under the skin or into a vein. The study focuses on side effects an…

This study looks at how a new drug called LY3537031 gets into the blood and how the body clears it. It involves 46 healthy volunteers who receive the drug either under the skin in different spots or into a vein. The goal is to understand the best way to give the drug and check it…

This study looks at how fasting and temporarily stopping the diabetes drug dulaglutide affect how much food and liquid stays in the stomach after a meal. About 20 people with type 2 diabetes will have their stomachs checked with ultrasound after eating. The goal is to understand …

This study tests a new drug called LY3981314 in healthy people to see if it is safe and how the body handles it. About 76 participants will receive a single injection under the skin and be monitored for up to 25 weeks. The goal is to gather safety information, not to treat any di…

This study follows 1,400 people with early-stage Alzheimer's or mild cognitive impairment to understand how the disease affects healthcare costs and daily life over time. Participants are not given any experimental treatment. The goal is to gather information for research purpose…

This early-stage study is testing a single dose of remternetug in 24 healthy Chinese adults to see if it is safe and how the body processes it. Participants will have blood tests and be monitored for side effects over about 25 weeks. The study does not aim to treat any disease, b…

This study looks at how long you need to fast and how stopping the diabetes/weight-loss drug tirzepatide changes the amount of food left in your stomach after a meal. Researchers will use ultrasound to check stomach contents in 40 people with type 2 diabetes or obesity. The goal …

This study looks at how well three different tablet versions of the drug LY4100511 are absorbed by the body in 48 healthy adults. It also checks if taking a common stomach acid medicine (a proton pump inhibitor) changes absorption. The goal is to find the best tablet form for fut…